- Home
- SCZM vs LTGO Comparison
SCZM vs LTGO Comparison
Compare SCZM & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SCZM | LTGO |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | United States |
| Employees | 455 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.1M | 924.9M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | SCZM | LTGO |
|---|---|---|
| Price | $7.57 | $14.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $17.16 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 358.8K | 201.0K |
| Earning Date | 11-27-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.52 | N/A |
| Revenue Next Year | $13.48 | N/A |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.61 | $13.26 |
| 52 Week High | $17.65 | $25.93 |
Technical Indicators
Market Signals| Indicator | SCZM | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 42.74 |
| Support Level | $5.95 | $13.50 |
| Resistance Level | $7.01 | $17.67 |
| Average True Range (ATR) | 0.37 | 1.39 |
| MACD | -0.09 | 0.08 |
| Stochastic Oscillator | 8.06 | 29.71 |
Price Performance
Historical ComparisonAbout SCZM Santacruz Silver Mining Ltd. Common Shares
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.